These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 31693749)
21. The use of ivermectin in controlling an outbreak of scabies in a prison. Leppard B; Naburi AE Br J Dermatol; 2000 Sep; 143(3):520-3. PubMed ID: 10971323 [TBL] [Abstract][Full Text] [Related]
22. A health club for a community school in south-eastern Nigeria: influence on adult perception of onchocerciasis and compliance with community-based ivermectin therapy. Shu EN; Onwujekwe EO; Lokili P; Okonkwo PO Trop Med Int Health; 2000 Mar; 5(3):222-6. PubMed ID: 10747286 [TBL] [Abstract][Full Text] [Related]
23. Influence of health education on community participation in rapid assessment of onchocerciasis prior to distribution of ivermectin. Shu EN; Nwadike KI; Onwujekwe EO; Ugwu OC; Okonkwo PO East Afr Med J; 1999 Jun; 76(6):320-3. PubMed ID: 10750518 [TBL] [Abstract][Full Text] [Related]
24. [Evaluation of practices in the management of scabies in children]. Lê MS; Richard MA; Baumstarck K; Hesse S; Gaudy-Marqueste C; Grob JJ; Mallet S; Ann Dermatol Venereol; 2017 May; 144(5):341-348. PubMed ID: 28408046 [TBL] [Abstract][Full Text] [Related]
25. Onchocerciasis in the Amazonian focus of southern Venezuela: altitude and blackfly species composition as predictors of endemicity to select communities for ivermectin control programmes. Vivas-Martinez S; Basáñez MG; Grillet ME; Weiss H; Botto C; García M; Villamizar NJ; Chavasse DC Trans R Soc Trop Med Hyg; 1998; 92(6):613-20. PubMed ID: 10326102 [TBL] [Abstract][Full Text] [Related]
26. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy. Cupp EW; Sauerbrey M; Richards F Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094 [TBL] [Abstract][Full Text] [Related]
27. Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years. Greter H; Mmbando B; Makunde W; Mnacho M; Matuja W; Kakorozya A; Suykerbuyk P; Colebunders R BMJ Open; 2018 Mar; 8(3):e017188. PubMed ID: 29605818 [TBL] [Abstract][Full Text] [Related]
28. Oral ivermectin for infants and children under 15 kg appears to be a safe and effective treatment for scabies. Morris-Jones R Br J Dermatol; 2020 Apr; 182(4):835-836. PubMed ID: 31885077 [No Abstract] [Full Text] [Related]
29. A method to determine the coverage of ivermectin distribution in onchocerciasis-control programmes. Schwartz EC; Renk J; Hopkins AD; Huss R; Foster A Ann Trop Med Parasitol; 1998 Oct; 92(7):793-6. PubMed ID: 9924537 [TBL] [Abstract][Full Text] [Related]
30. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward. Ndyomugyenyi R; Lakwo T; Habomugisha P; Male B Ann Trop Med Parasitol; 2007 Jun; 101(4):323-33. PubMed ID: 17524247 [TBL] [Abstract][Full Text] [Related]
31. Crusted scabies in an immunocompetent child: treatment with ivermectin. Gladstone HB; Darmstadt GL Pediatr Dermatol; 2000; 17(2):144-8. PubMed ID: 10792808 [TBL] [Abstract][Full Text] [Related]
32. Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded? Twum-Danso NA Ann Trop Med Parasitol; 2004 Mar; 98(2):99-114. PubMed ID: 15035720 [TBL] [Abstract][Full Text] [Related]
33. Risk factors for treatment failure in scabies: a cohort study. Aussy A; Houivet E; Hébert V; Colas-Cailleux H; Laaengh N; Richard C; Ouvry M; Boulard C; Léger S; Litrowski N; Benichou J; Joly P; Br J Dermatol; 2019 Apr; 180(4):888-893. PubMed ID: 30376179 [TBL] [Abstract][Full Text] [Related]
34. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. Katabarwa M; Eyamba A; Habomugisha P; Lakwo T; Ekobo S; Kamgno J; Kuete T; Ndyomugyenyi R; Onapa A; Salifou M; Ntep M; Richards FO Trop Med Int Health; 2008 Sep; 13(9):1196-203. PubMed ID: 18631308 [TBL] [Abstract][Full Text] [Related]
35. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Bécourt C; Marguet C; Balguerie X; Joly P Br J Dermatol; 2013 Oct; 169(4):931-3. PubMed ID: 23724970 [TBL] [Abstract][Full Text] [Related]
36. Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Kyelem D; Sanou S; Boatin B; Medlock J; Coulibaly S; Molyneux DH Ann Trop Med Parasitol; 2003 Dec; 97(8):827-38. PubMed ID: 14754495 [TBL] [Abstract][Full Text] [Related]
37. Effect of repeated treatments with ivermectin on the incidence of onchocerciasis in northern Cameroon. Boussinesq M; Chippaux JP; Ernould JC; Quillevere D; Prod'hon J Am J Trop Med Hyg; 1995 Jul; 53(1):63-7. PubMed ID: 7625535 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of endemic scabies with allethrin, permethrin and ivermectin. Evaluation of a treatment strategy]. Paasch U; Haustein UF Hautarzt; 2001 Jan; 52(1):31-7. PubMed ID: 11220236 [TBL] [Abstract][Full Text] [Related]
39. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status. Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580 [TBL] [Abstract][Full Text] [Related]